ZYME - Zymeworks Inc.About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $45.17 | Open | $45.17 |
| Volume | 292.8K | Market Cap | 2.061B |
| Yield | Last Dividend |
| Checkpoint Therapeutics, Nano-X Imaging ... | 09/11/20 |
| Gainers: Checkpoint Therapeutics (NASDAQ:CKPT) +29%, Nano-X Imaging (NASDAQ:NNOX) +21%, Biofrontera AG (NASDAQ:BFRA) +20%, Zymeworks (NYSE:ZYME) +14%,... | |
| Zymeworks to Present at Upcoming Investo... | 09/03/20 |
| VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional bioth... | |
| Zymeworks Reports 2020 Second Quarter Fi... | 08/05/20 |
| VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional bioth... | |
| Zymeworks Corporate Update Webcast and C... | 07/08/20 |
| VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional bioth... | |
| Zymeworks Announces New Multispecific An... | 07/08/20 |
| Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it and longti | |
| Zymeworks Announces Corporate Update Web... | 06/30/20 |
| Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that it will host a w | |
| Zymeworks to Present at the Jefferies 20... | 05/28/20 |
| VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional thera... | |
| Zymeworks Reports 2020 First Quarter Fin... | 05/07/20 |
| VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional bioth... | |
| Applied BioMath, LLC Announces Collabora... | 05/04/20 |
| CONCORD, Mass., May 4, 2020 /PRNewswire/ -- Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechani... | |
| Zymeworks Reports 2019 Year-End Financia... | 03/02/20 |
| VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional bioth... | |
| Zymeworks to Present at Raymond James 41... | 02/24/20 |
| VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional therap... | |
| The Daily Biotech Pulse: Roche Reports P... | 01/23/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 22) ... | |
| Zymeworks Highlights 2019 Achievements a... | 01/13/20 |
| VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional bioth... | |
| Zymeworks Announces Agreement with Pfize... | 01/12/20 |
| VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional thera... | |
| The Daily Biotech Pulse: Positive Data R... | 01/10/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 9) A... | |
| Zymeworks to Present at the J.P. Morgan ... | 01/07/20 |
| VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional thera... | |
| Zymeworks Highlights Advancing Clinical ... | 11/22/19 |
| SINGAPORE--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today ann... | |
| Zymeworks Announces Selection of ZW25 Ab... | 11/18/19 |
| VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional thera... | |
| Zymeworks Files Automatic Shelf Registra... | 11/05/19 |
| VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical???stage biopharmaceutical company developing multifunctional the... | |
| Zymeworks to Present at Stifel 2019 Heal... | 11/04/19 |
| VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional thera... | |
| Earnings Preview: Zymeworks Inc. (ZYME) ... | 10/29/19 |
| Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared... | |
| Zymeworks Inc. (ZYME) Reports Q2 Loss, T... | 08/02/19 |
| Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -10.91% and 8.72%, respectively, for the quarter ended June 2019. Do the numbers hol... | |
| Zymeworks Inc. (ZYME) Expected to Beat E... | 07/31/19 |
| Zymeworks Inc. (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with ... | |
| GSK expands collaboration with Zymeworks | 05/16/19 |
| No summary available. | |
| Zymeworks beats by $0.09, beats on reven... | 05/02/19 |
| No summary available. | |
| Zymeworks (ZYME) Presents At Bloom Burto... | 04/30/19 |
| No summary available. | |
| Eyes On Apple, Uber, F8 And Avengers (St... | 04/28/19 |
| No summary available. | |
| Stocks To Watch: Eyes On Apple, Uber, F8... | 04/27/19 |
| No summary available. | |
| Zymeworks nabs $3.5M milestone from Daii... | 04/25/19 |
| No summary available. | |
| Zymeworks launches mid-stage trial for Z... | 04/15/19 |
| No summary available. | |
| Strong Buy rating | 08/06/20 |
| SVB Leerink initiates coverage with Outperform rating and announces Price Target of $45.00 | |
| Buy rating | 07/09/20 |
| HC Wainwright & Co. maintains Buy rating and lowers Price Target from $60.00 to $54.00 | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
